Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

NCT06855628 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

10

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Glioma
GBM

Interventions

OTHER: [6,6-²H₂]-Glucose

Sponsor

Stanford University

Collaborators

[object Object]
[object Object]